The role of AP-1 in glucocorticoid resistance in leukaemia.
Glucocorticoids are used in the treatment of acute lymphoblastic leukaemia (ALL) and chronic lymphocytic leukaemia (CLL) but many patients develop glucocorticoid resistance on relapse. The ligand-activated glucocorticoid receptor inhibits activity of the AP-1 transcription factor and the purpose of this study was to test the hypothesis that up-regulation or overexpression of AP1-binding activity may be an important mechanism of glucocorticoid resistance in ALL and CLL. In vitro sensitivity of patient blasts to prednisolone was measured using th
Department of Child Health, University of Newcastle upon Tyne, UK.
S
S
Bailey
A G
AG
Hall
A D
AD
Pearson
C P
CP
Redfern
D000328:Adult; D001483:Base Sequence; D015152:Blotting, Northern; D015153:Blotting, Western; D002675:Child, Preschool; D017931:DNA Primers; D019008:Drug Resistance, Neoplasm; D005260:Female; D005938:Glucocorticoids / Q000494:pharmacology*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000378:metabolism / Q000473:pathology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000378:metabolism / Q000473:pathology*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D016755:Proto-Oncogene Proteins c-jun / Q000378:metabolism; D018808:Transcription Factor AP-1 / Q000502:physiology*
D017931:DNA Primers; D005938:Glucocorticoids; D016760:Proto-Oncogene Proteins c-fos; D016755:Proto-Oncogene Proteins c-jun; D018808:Transcription Factor AP-1